AI Article Synopsis
- * RNA-based therapies, especially using microRNAs and small interfering RNAs (siRNAs), have shown potential for treating various diseases, including cardiovascular disease (CVD).
- * Despite their promise, RNA therapies face challenges like poor binding, instability, delivery issues, immune responses, and unintended effects, which need to be addressed for effective medication development.
Article Abstract
Atherosclerosis represents a pathological state that affects the arterial system of the organism. This chronic, progressive condition is typified by the accumulation of atheroma within arterial walls. Modulation of RNA molecules through RNA-based therapies has expanded the range of therapeutic options available for neurodegenerative diseases, infectious diseases, cancer, and, more recently, cardiovascular disease (CVD). Presently, microRNAs and small interfering RNAs (siRNAs) are the most widely employed therapeutic strategies for targeting RNA molecules, and for regulating gene expression and protein production. Nevertheless, for these agents to be developed into effective medications, various obstacles must be overcome, including inadequate binding affinity, instability, challenges of delivering to the tissues, immunogenicity, and off-target toxicity. In this comprehensive review, we discuss in detail the current state of RNA interference (RNAi)-based therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/bs.pmbts.2023.12.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
Latin American Institute for Brain Health (BrainLat), Universidad Adolfo Ibañez, Santiago, Chile.
Background: The content of circulating exosomes has been observed to be altered in response to changes in physiological and pathological conditions, and they are detectable in different human fluids such as blood. Studies focused on the quantification of Aβ and tau proteins, as molecules contained within exosomes, suggest that they are related with Alzheimer disease (AD) and frontotemporal dementia (FTD) development, demonstrated that plasma-derived exosome analysis is a good approach for searching for biomarkers in the development of dementia. Our aim is to identify new blood biomarkers to detect the AD or FTD in the Chilean population using machine learning based on exosomal miRNAs.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Oregon Health & Science University, Portland, OR, USA.
Background: Alzheimer's disease (AD) is the fifth leading cause of death for individuals aged 65 and older. Since FDA approved therapies have limited efficacy, there is a need to develop new treatments based on a better understand of pathological changes occurring in tissues from humans with AD. Central nervous system cells utilize extracellular vesicles (EVs) to package and secrete miRNAs where they mediate cell-to-cell communication.
View Article and Find Full Text PDFSonic Hedgehog signaling regulates the optimal differentiation pace from early-stage mesoderm to cardiogenic mesoderm in mice.
Dev Growth Differ
January 2025
Division of Anatomy and Developmental Biology, Department of Anatomy, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Sonic Hedgehog (Shh), encoding an extracellular signaling molecule, is vital for heart development. Shh null mutants show congenital heart disease due to left-right asymmetry defects stemming from functional anomaly in the midline structure in mice. Shh signaling is also known to affect cardiomyocyte differentiation, endocardium development, and heart morphogenesis, particularly in second heart field (SHF) cardiac progenitor cells that contribute to the right ventricle, outflow tract, and parts of the atrium.
View Article and Find Full Text PDFBackground: Increasing data indicates that the pathophysiology of microtubule associated protein tau is mediated by its interactions with RNA and RNA binding proteins via stress granules (SGs) and the translational stress response. Aquinnah now reports identifying small molecule compounds that inhibit tau/TIA1 SGs in neuronal cell lines and show strong in vivo efficacy in a classic mouse model of tauopathy.
Method: Compounds identified using high content imaging screening in SH-SY5Y neuroblastoma cells, inducibly over-expressing tau::GFP and TIA1::mKate2, following exposure to stressor.
Drug Development.
Alzheimers Dement
December 2024
Columbia University Irving Medical Center, New York, NY, USA.
Background: Genetic studies indicate a causal role for microglia, the innate immune cells of the central nervous system (CNS), in Alzheimer's disease (AD). Despite the progress made in identifying genetic risk factors, such as CD33, and underlying molecular changes, there are currently limited treatment options for AD. Based on the immune-inhibitory function of CD33, we hypothesize that inhibition of CD33 activation may reverse microglial suppression and restore their ability to resolve inflammatory processes and mitigate pathogenic amyloid plaques, which may be neuroprotective.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!